DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06132477

RecruitingPhase 4

Impact GLP-1 Agonists Following Bariatric

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

1

Recruiting sites

1

Enrollment

150

estimated

Study population

Bariatric Surgery, Obesity / overweight

Key I/E criterion

•BMI 30-80

Primary endpoints

•BMI, change•Effect of GLP1-RA on circulating bile acids and metabolites•Effector of GLP1-RA on gut microbiome diversity

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06132477
Org study ID2098885

Timeline

Milestones

Study first posted2023-11-15actual
Study start2024-02-01actual
Last update posted2026-01-22actual
Primary completion2028-07estimated (month precision)
Study completion2030-07estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Bariatric SurgeryObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Greater than 18 years of age

2. Participation in care by one of the surgeons at MU Health Care

3. Undergoing surgical weight loss through the Weight Management and Metabolic Center

4. Body mass index of 30-80 kg/m2

5. Meet insurance criteria, as set forth by the patient's insurance policy, to qualify for coverage for weight loss surgery or as a self-pay patient for the weight loss procedure

6. Planned laparoscopic Roux-en-Y gastric bypass, sleeve gastrectomy, revisional weight loss surgery, or duodenal switch or modification of. If patients are not willing to be randomized they will not be enrolled as randomized but can still participate having samples collected.

7. Willingness to have blood collected before and after surgical procedure at defined points or at minimum have clinical data collected.

8. Willingness to have clinical data entered into a prospective database

9. Additional specimens collected as stated in the protocol will be offered but collection not mandated.

5. Taking a GLP-1 agonist as part of their routine medical care apart from any planned surgical procedure. The current standard of care regarding continuation or discontinuation of GLP-1 agonists has not been established and is at the discretion of members of the patient's medical team but to be included the patient and medical care team must be willing to continue or discontinue the GLP-1 agonist after surgery depending on the randomized group.

Exclusion criteria

1. Pregnant patient

2. Desire to not participate

3. Age less than 18

4. Patient fails to fulfill insurance mandated criteria and is not interested in paying cash for their procedure

5. Not taking a GLP-1 agonist as part of standard medical care

6. Unwilling to follow-up at required postoperative visits

7. Unwilling to stop GLP-1 agonist if randomized into group to stop GLP-1 agonist or unwilling to continue the GLP-1 agonist if randomized into that respective group. If chooses to continue or discontinue the medication apart from randomization the patient can still participate as a non-randomized participant

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Weight & body composition
1
Glycemic / diabetes
1
Patient-reported / QoL
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Effect of GLP1-RA on weight loss

Time frame:6 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Effect of GLP1-RA on Glycemic control

Time frame:6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Effect of GLP1-RA on satiety and hunger

Time frame:6 months

change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Effect of GLP1-RA on circulating bile acids and metabolites

Time frame:6 months

descriptive

Primary/protocol endpoint/low confidence

Effector of GLP1-RA on gut microbiome diversity

Time frame:6 months

descriptive

Publications (37)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.